Incidence of hematological toxicities on bispecifics for multiple myeloma published trials
| Reference . | Population . | Drug/target . | N* . | Anemia& . | Neutropenia& . | Thrombocytopenia& . | Febrile Neutropenia& . | Lymphopenia& . | Low IgG& . | HLH& . | DIC& . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Usmani et al. (2021)27 | Adult R/R MM | Teclistamab BCMA × CD3 | 40 | 20(50%)/ 11(28%) | 26(65%)/ 16(40%) | 18(45%)/8(20%) | NA/NA | 7(9.6%)/ 7(9.6%) | 14(9%)/NA | NA/NA | NA/NA |
| Moreau et al. (2022)28 ¥ | Adult R/R MM | Teclistamab BCMA × CD3 | 165 | 86(52.1%)/ 61(37%) | 117(70.9%)/ 106(64%) | 66(40%)/35(21%) | 4(2.4%)/NA | 57(34.5%)/ 54(32.7%) | 123(74.5%)/NA | NA/NA | NA/NA |
| D'Souza et al. (2022)31 | Adult R/R MM | ABBV-383 BCMA × CD3 | 124 | 36(29%)/ 20(16%) | 46(37%)/ 42(34%) | 29(23%)/15(12%) | NA/NA | 19(15%)/16(13%) | 17(14%)/NA | NA/NA | NA/NA |
| Chari et al. (2022)33 # | Adult R/R MM | Talquetamab GPRC5D × CD3 | 130 | 63(48.5%)/ 36(27.7%) | 67(51.5%)/ 59(45.4%) | 39(30%)/26(20%) | NA/3(2.3%) | 42(32.3%)/ 42(32.3%) | NA/NA | NA/NA | NA/NA |
| Reference . | Population . | Drug/target . | N* . | Anemia& . | Neutropenia& . | Thrombocytopenia& . | Febrile Neutropenia& . | Lymphopenia& . | Low IgG& . | HLH& . | DIC& . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Usmani et al. (2021)27 | Adult R/R MM | Teclistamab BCMA × CD3 | 40 | 20(50%)/ 11(28%) | 26(65%)/ 16(40%) | 18(45%)/8(20%) | NA/NA | 7(9.6%)/ 7(9.6%) | 14(9%)/NA | NA/NA | NA/NA |
| Moreau et al. (2022)28 ¥ | Adult R/R MM | Teclistamab BCMA × CD3 | 165 | 86(52.1%)/ 61(37%) | 117(70.9%)/ 106(64%) | 66(40%)/35(21%) | 4(2.4%)/NA | 57(34.5%)/ 54(32.7%) | 123(74.5%)/NA | NA/NA | NA/NA |
| D'Souza et al. (2022)31 | Adult R/R MM | ABBV-383 BCMA × CD3 | 124 | 36(29%)/ 20(16%) | 46(37%)/ 42(34%) | 29(23%)/15(12%) | NA/NA | 19(15%)/16(13%) | 17(14%)/NA | NA/NA | NA/NA |
| Chari et al. (2022)33 # | Adult R/R MM | Talquetamab GPRC5D × CD3 | 130 | 63(48.5%)/ 36(27.7%) | 67(51.5%)/ 59(45.4%) | 39(30%)/26(20%) | NA/3(2.3%) | 42(32.3%)/ 42(32.3%) | NA/NA | NA/NA | NA/NA |
DIC, disseminated intravascular coagulation; HLH, hemophagocytic lymphohystiocytosis; MM, multiple myeloma; NA, not available; R/R, relapsed/refractory; RP2P, recommended phase 2 dose.
N is the population considered for that extracted data, which may be the whole cohort or a subpopulation.
Adverse event, any grade(%)/grade ≥3(/%).
Data from cohort of phase 1 and cohort of phase 2 that used the RP2D; N = 165.
Data from all subcutaneous cohorts (supplement material); N = 130.